Skip to main content
OpenTrials
Completed

NCT Number: NCT03566979

Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain

To evaluate analgesic onset, efficacy, and safety of a single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets compared with two commercial naproxen sodium products (two naproxen sodium 220 mg tablets and two naproxen sodium 220 mg liquid gels capsules) and placebo in the dental pain model following third-molar extractions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

17 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

JBR Clinical Research

Salt Lake City, Utah, 84107, United States

About this study

This is a single-dose, randomized, double-blind, placebo- and active- controlled, parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of 440 mg of naproxen sodium administered as two Test NPX 220 mg tablets compared with two commercial products and placebo over a twelve-hour period after third-molar extractions. Subjects will undergo dental extraction of three or four third molars.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 17 - 50 years old
  • Weigh 100 pounds or greater and have a body mass index (BMI) of 17.5 to 30.4 (inclusive) at screening
  • Dental extraction of three or four third molars
  • Meets post-surgical pain
  • Females of childbearing potential and males agree to contraceptive requirements of study
  • Have a negative urine drug screen at screening, and on day of surgical procedure

Exclusion criteria

  • Pregnant female, breastfeeding, trying to be pregnant or male with pregnant partner or partner currently trying to become pregnant
  • Have a known allergy or hypersensitivity to naproxen or other NSAIDs, including aspirin, or to acetaminophen, hydrocodone or other opioids
  • Not able to swallow large tablets or capsules
  • History of any condition (s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study
  • Use analgesics 5 or more times per week
  • History of chronic tranquilizer use, heavy drinking, substance abuse as judged by investigator site staff within last 5 years
  • Use of immunosuppressive drugs within 2 weeks of screening
  • History of endoscopically documented peptic ulcer disease or bleeding disorder in last 2 years

Treatment and study plan

Test naproxen sodium tablet

Drug

Single dose of 2 test naproxen sodium 220 mg tablets

Other names: Test NPX tablet

Commercial naproxen sodium tablet

Drug

Single dose of 2 naproxen sodium 220 mg tablets

Other names: Commercial NPX tablet

Commercial naproxen sodium liquid gels capsule

Drug

Single dose of 2 naproxen sodium 220 mg liquid gel capsules

Other names: Commercial NPX liquid gels capsule

Placebo Tablet

Drug

2 placebo tablets

Primary outcomes

  1. Time to Confirmed Perceptible Pain Relief

    Time frame: 12 hours

    Minutes until confirmed first perceptible pain relief was achieved. Stopwatch is started after the participant takes the study medication. The participant is instructed to stop the stopwatch when they first begin to feel any pain relief. The first perceptible pain relief is confirmed if the participant also stopped the second stopwatch indicating meaningful pain relief.

Secondary outcomes

  1. Percentage of Participants With Confirmed Perceptible Pain Relief From 45 Minutes to Successively Earlier Minutes in One-minute Increments

    Time frame: Up to 45 minutes after dosing

    Percentage of participants with confirmed perceptible pain relief from 45 minutes to successively earlier minutes in one-minute increments were reported.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo- and Active- Controlled, Efficacy and Safety Study of a Test Naproxen Sodium 220 mg Tablet in Postoperative Dental Pain

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 25, 2018
Registry last updated
Apr 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.